Monday, Sep 16, 2024 · SEC filings
What the smart money revealed on Sep 16
402 insider filings came in. We hid 61 planned (10b5-1) sellers and 189 people whose filings were routine, like grants and tax withholding.
3 insiders at Zenas BioPharma (ZBIO) bought $27.6M of stock
Roles: Director. Several insiders buying in the same few days is rare.
Liquidia (LQDA) Director Paul Manning bought $3M
337,078 shares on the open market. Not a grant or an option exercise. Their past buys: 3 of 5 checked quarters beat the typical stock 6 months later.
Inhibrx Biosciences (INBX) CEO Mark Lappe bought $629K
40,000 shares on the open market. Not a grant or an option exercise.
Lakeland Financial (LKFN) Senior Vice President Stephanie Leniski bought $293K
4,500 shares on the open market. Not a grant or an option exercise.
Fathom (FTHM) Director Scott Flanders bought $285K
100,000 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 5 checked quarters beat the typical stock 6 months later.
AppLovin (APP) CEO and Chairperson Arash Foroughi sold $21.6M
Not marked as a planned 10b5-1 sale. Sold 5% of the shares they held directly. Still holds 3.89M shares.
Celsius (CELH) CEO John Fieldly sold $21.4M
Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day. Still holds 1.26M shares directly.
Asset Entities (ASST) COO Arman Sarkhani sold $473K
Not marked as a planned 10b5-1 sale. Sold every share held directly.
Show 48 more real buys
Show 71 more real sales
13F season
Holdings as of Jun 30, 2024 were due Aug 14
54 funds have filed. 50 filed for the quarter before.
Biggest real insider buys, Sep 10–16
Open-market buys by officers and directors, filed in the 7 days up to Sep 16.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.